hki-357
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2008 (NCT00550381)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
ERBB2 inhibitor
- Epidermal growth factor receptorINHIBITOR
Epidermal growth factor receptor inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C- Mol. weight
- 574.06 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL178654 ↗
Also known as
- hki-357
- hki-357
- hki-357
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00550381 | Phase 1 | Jan 1, 2008 | Pfizer, Wyeth |
Showing 1 of 1 trials
Page 1 / 1